Metastatic pancreatic and lung cancer patient in complete remission following immunotherapy: A case report and review of literature
Metadatos
Afficher la notice complèteAuteur
Martínez Galán, Joaquina; Jiménez Luna, Cristina; Rodríguez, Isabel; Maza, Elisabeth; García Collado, Carlos; Rodríguez Fernández, Antonio; López Hidalgo, Javier Luis; Caba Pérez, OctavioEditorial
Baishideng Publishing Group Inc.
Materia
Pancreatic ductal adenocarcinoma Lung cancer; Immunotherapy Pembrolizumab Programmed cell death protein- 1 Case report
Date
2024-05-15Referencia bibliográfica
Martínez-Galán, J., Jiménez-Luna, C., Rodriguez, I., Maza, E., García-Collado, C., Rodríguez-Fernández, A., López-Hidalgo, J. L., & Caba, O. (2024). Metastatic pancreatic and lung cancer patient in complete remission following immunotherapy: A case report and review of literature. World journal of gastrointestinal oncology, 16(5), 2233–2240. https://doi.org/10.4251/wjgo.v16.i5.2233
Patrocinador
Spanish Ministry of Universities María Zambrano postdoctoral fellowship; Next Generation European UnionRésumé
The lack of specific symptoms in patients and the absence of a reliable and well-stablished diagnostic method,
makes advanced pancreatic ductal adenocarcinoma (PDAC) the most common clinical appearance of pancreatic cancer
cases. In these circumstances, surgical resection, the only curative approach for this malignancy, is unaffordable, leading to
very low survival outcomes. Immunotherapy is a recent approach that has been studied in many cancer types showing
encouraging results, but it has not been sufficiently investigated in PDAC. We report the case of a patient with unresectable
PDAC that progressed to metastasis after treatment with chemoradiation, who showed an outstanding response to immuno-
therapy with pembrolizumab, achieving a complete remission within a few months, which was maintained until the end of
treatment. Currently, the patient continues in disease-free state.